-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Ulcerative colitis (UC) is a chronic inflammatory bowel disease.
UC diagnoses about 20% of patients with acute severe ulcerative colitis (ASUC), which has been reported to be effective in the treatment of IFX and cyclosporine (CSA), but is being increasing clinical use due to the need to closely monitor CSA drug levels.
studies have shown that patients with high C-reactive protein (CRP) and low serum albumin levels may be a potential cause of IFX treatment failure.
study aims to identify risk factors for colonectomy in high-risk ASUC patients who fail to use IFX.
reviewed clinical data on patients hospitalized with acute severe ulcerative colitis who had failed to receive infrasotretic therapy with glucoticoids between July 2012 and June 2017.
used a logical regression analysis to determine the predicted indicators for 90-day and one-year colorectomy and to compare the 90-day and 1-year colonectomy rates of patients receiving 5 mg / kg and 10 mg / kg IFX rescue doses.
63 patients in this study met the standard.
29 patients were treated at doses of 5 mg / kg and 34 patients were treated at 10 mg / kg in inflixi monoantigen.
serum albumin (OR 0.10; p - 0.04) and the percentage of neutral granulocytes (OR 1.2; p -0.02) is an independent predictive indicator of a 90-day colonectomy.
serum albumin ≤2.5 g/dl and neutral granulocyte count≥13% had a 100% positive prediction for 90-day colonectomy.
in the 5 mg / kg and 10 mg / kg Inverlixi monoantigen groups, the unaltered 90-day and 1-year colonectomy rates were similar.
adjusting the mixing factors, inflixi monoantigen 10 mg / kg dose to 90 days (OR 0.07; p s 0.06) has potential protective effects, but for 1 year colonectomy (OR 0.19; p - 0.16) has no protective effect.
study concluded, the authors said: Low hemoglobin and low serum albumin are independent predictors of the failure of infringing in patients with severe ulcerative colons who received inflexid anti-rescue therapy.
serum albumin ≤2.5 g / dl combined neutral granulocyte count≥13% had a 100% positive prediction for 90-day colonectomy.
